Earlier this month, the ASCO Post featured recent research and analysis from MDoutlook. The article focused on the downstream implications of the FDA revoking the breast cancer indication for bevacizumab on Friday November 18, 2011.
MDoutlook was the first source to report on the global clinical impact of this news through our unique and proprietary oncology intelligence platform now reaching more than 62,000 cancer treaters globally. The research was conducted over a 3-day period directly following the decision with the results from 232 oncologists posted on Wednesday, November 23, 2011 in OBR Daily.
For more information on our capabilities to assess, analyze and report on market-moving events in specialty diseases, and on our customized research programs please contact us at [email protected], 888.368.8566 or internationally +1.404.496.4136. A quick overview of our capabilities can be download through this download: MDoutlook capabilities.